UK Allergies Worsen: New Hope or Old Dangers?

Severe hay fever is increasingly impacting lives in the UK, with prolonged seasons and early onset, even in winter months. This escalating issue leads many sufferers to seek drastic solutions, including the controversial Kenalog steroid injection. Though available privately for £75-£90, this jab, which was discontinued by the NHS in 2018 due to safety concerns, carries risks such as weakened immunity and potential long-term health damage, including impacts on bone health.

Amidst these concerns, a more effective and safer treatment, allergen immunotherapy (AIT), is gaining attention. This three-year process desensitises the immune system to pollen allergens. While NHS trials show significant improvement, awareness among UK medical professionals is critically low. Barriers include limited curriculum inclusion of allergy treatment and a scarcity of specialist allergy clinics, leading to long waiting times. For instance, Germany desensitises hundreds of patients for every one in the UK.

Despite NICE recommending AIT to the NHS, access remains a significant hurdle. Privately, the treatment can cost around £130 per month, totaling approximately £4,200 over three years. A National Allergy Strategy is set to be published, aiming to address these access issues. While many individuals, like the author, are still resorting to risky injections for immediate relief, the push for greater awareness and availability of AIT offers future hope for those suffering from severe allergies.